BioSpace News Archive

Carisma Therapeutics expands on foundational first-of-its-kind engineered macrophage cell therapy platform study and explores time-reducing isolation-to-infusion pathway

New data from the Pennsylvania Medical Society highlights some of the economic challenges that physician offices and other medical facilities have faced due to the drop in non-emergency care during the COVID-19 pandemic.

Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies

Luxembourg becomes the first country to launch a systematic nationwide testing as part of the Proactive Mitigation Program designed by its COVID-19 Task Force

Data to be presented at 2020 AACR Annual Meeting show HPK1 inhibition produced robust anti-tumor response in mouse model

Xencor, Inc. announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody programs and an IL-12-Fc cytokine program at the second session of the American Association for Cancer Research Virtual Annual Meeting, being held June 22-24, 2020.

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the pricing of its underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $28.00 per share.

Transgene and BioInvent International AB announce new highly promising preclinical data demonstrating the broad therapeutic potential of BT-001, an anti-CTLA4 antibody-encoding oncolytic virus, against solid tumors.

First in human trial with the lead candidate BI-1808 - a ligand-blocking FcgR-engaging anti-TNFR2 antibody - on track to enter clinical trials 2020

BT-001 leverages the combined strengths of BioInvent’s n-CoDeR®/F.I.R.S.T™ platforms and Transgene’s Invir.IO™ platform